SHR-2173 clinical trials
Also written SHR-2173.
How each study uses SHR-2173 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SHR-2173 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test SHR-2173.
- Apr 2027A Study of SHR-2173 in Participants With Primary IgA NephropathyPhase 2 · Guangdong Hengrui Pharmaceutical Co., Ltd
- Jun 2027A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus NephritisPhase 2 · Guangdong Hengrui Pharmaceutical Co., Ltd
- Aug 2027Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous NephropathyPhase 2 · Guangdong Hengrui Pharmaceutical Co., Ltd
- Sep 2027A Phase II Study of SHR-2173 Injection in Patients With Myasthenia GravisPhase 2 · Guangdong Hengrui Pharmaceutical Co., Ltd
Studies
Open first, then newest update. How each study uses SHR-2173 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Phase II Study of SHR-2173 Injection in Patients With Myasthenia GravisRecruitingPhase 2Guangdong Hengrui Pharmaceutical Co., LtdNCT07622342Written as SHR-2173 injection
- A Study of SHR-2173 in Participants With Systemic Lupus ErythematosusRecruitingPhase 2Guangdong Hengrui Pharmaceutical Co., LtdNCT07299422Written as SHR-2173 Injection
- Phase I Study of SHR-2173 Injection in Patients With Primary Immune ThrombocytopeniaRecruitingPhase 1Guangdong Hengrui Pharmaceutical Co., LtdNCT07206758Written as SHR-2173 Injection
- A Study of SHR-2173 in Participants With Primary IgA NephropathyRecruitingPhase 2Guangdong Hengrui Pharmaceutical Co., LtdNCT07354932Written as SHR-2173 injection
- Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous NephropathyRecruitingPhase 2Guangdong Hengrui Pharmaceutical Co., LtdNCT07289763Written as SHR-2173 injection
- A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus NephritisRecruitingPhase 2Guangdong Hengrui Pharmaceutical Co., LtdNCT07229742Written as SHR-2173 Injection
- A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus ErythematosusCompletedPhase 1Guangdong Hengrui Pharmaceutical Co., LtdNCT06955598Written as SHR-2173
- Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-2173 in Healthy SubjectsCompletedPhase 1Guangdong Hengrui Pharmaceutical Co., LtdNCT06995001Written as SHR-2173
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- A Phase II Study of SHR-2173 Injection in Patients With Myasthenia GravisOct 22, 2026NCT07622342